We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Catalyst Pharmaceutical (CPRX) Flat As Market Sinks: What You Should Know
Read MoreHide Full Article
In the latest trading session, Catalyst Pharmaceutical (CPRX - Free Report) closed at $17.55, marking no change from the previous day. This move was narrower than the S&P 500's daily loss of 0.41%. Elsewhere, the Dow lost 0.11%, while the tech-heavy Nasdaq lost 4.08%.
Coming into today, shares of the specialty drug company had gained 18.18% in the past month. In that same time, the Medical sector gained 6.85%, while the S&P 500 gained 6.51%.
Wall Street will be looking for positivity from Catalyst Pharmaceutical as it approaches its next earnings report date. On that day, Catalyst Pharmaceutical is projected to report earnings of $0.30 per share, which would represent year-over-year growth of 150%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $83.04 million, up 92.72% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $1.46 per share and revenue of $379.88 million. These totals would mark changes of +94.67% and +77.35%, respectively, from last year.
Any recent changes to analyst estimates for Catalyst Pharmaceutical should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 29.51% higher within the past month. Catalyst Pharmaceutical is currently a Zacks Rank #3 (Hold).
Looking at its valuation, Catalyst Pharmaceutical is holding a Forward P/E ratio of 12.03. This represents a premium compared to its industry's average Forward P/E of 11.96.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Catalyst Pharmaceutical (CPRX) Flat As Market Sinks: What You Should Know
In the latest trading session, Catalyst Pharmaceutical (CPRX - Free Report) closed at $17.55, marking no change from the previous day. This move was narrower than the S&P 500's daily loss of 0.41%. Elsewhere, the Dow lost 0.11%, while the tech-heavy Nasdaq lost 4.08%.
Coming into today, shares of the specialty drug company had gained 18.18% in the past month. In that same time, the Medical sector gained 6.85%, while the S&P 500 gained 6.51%.
Wall Street will be looking for positivity from Catalyst Pharmaceutical as it approaches its next earnings report date. On that day, Catalyst Pharmaceutical is projected to report earnings of $0.30 per share, which would represent year-over-year growth of 150%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $83.04 million, up 92.72% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $1.46 per share and revenue of $379.88 million. These totals would mark changes of +94.67% and +77.35%, respectively, from last year.
Any recent changes to analyst estimates for Catalyst Pharmaceutical should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 29.51% higher within the past month. Catalyst Pharmaceutical is currently a Zacks Rank #3 (Hold).
Looking at its valuation, Catalyst Pharmaceutical is holding a Forward P/E ratio of 12.03. This represents a premium compared to its industry's average Forward P/E of 11.96.
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.